Mafei Xu

Prof. Dr. Mafei Xu


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
LWLeiming Wang
Leiming Wang
CCChiang-Min Cheng
Chiang-Min Cheng
JQJun Qin
Jun Qin
MXMafei Xu
Mafei Xu
CKChung-Yang Kao
Chung-Yang Kao
MTMing-Jer Tsai
Ming-Jer Tsai
We identified inhibitors targeting COUP-TFII for the treatment of diseases including prostate cancer.

11 October 2019 in Science Advances
Verified
Journal Article
Open access
PDF file
MXMafei Xu
Mafei Xu
JQJun Qin
Jun Qin
LWLeiming Wang
Leiming Wang
HLHui-Ju Lee
Hui-Ju Lee
CKChung-Yang Kao
Chung-Yang Kao
STSophia Y. Tsai
Sophia Y. Tsai
We report a novel pathway where FANCD2 binds to nuclear receptors, COUP-TFII/TR4, to promote alternative lengthening of telomeres.

24 June 2020 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
CKChung-Yang Kao
Chung-Yang Kao
MXMafei Xu
Mafei Xu
LWLeiming Wang
Leiming Wang
SLShih-Chieh Lin
Shih-Chieh Lin
HLHui-Ju Lee
Hui-Ju Lee
MTMing-Jer Tsai
Ming-Jer Tsai
Parkinson’s disease (PD) is a neurodegenerative disorder featuring progressive loss of midbrain dopaminergic (DA) neurons that leads to motor symptoms. The etiology and pathogenesis of PD are not clear. We found that expression of COUP-TFII, an orphan nuclear receptor, in DA neurons is upregulated in PD patients through the analysis of public datasets. We show here that through epigenetic regulation, COUP-TFII contributes to oxidative stress, suggesting that COUP-TFII may play a role in PD pathogenesis. Elevated COUP-TFII expression specifically in DA neurons evokes DA neuronal loss in mice and accelerates the progression of phenotypes in a PD mouse model, MitoPark. Compared to control mice, those with elevated COUP-TFII expression displayed reduced cristae in mitochondria and enhanced cellular electron-dense vacuoles in the substantia nigra pars compacta. Mechanistically, we found that overexpression of COUP-TFII disturbs mitochondrial pathways, resulting in mitochondrial dysfunction. In particular, there is repressed expression of genes encoding cytosolic aldehyde dehydrogenases, which could enhance oxidative stress and interfere with mitochondrial function via 3,4-dihydroxyphenylacetaldehyde (DOPAL) buildup in DA neurons. Importantly, under-expression of COUP-TFII in DA neurons slowed the deterioration in motor functions of MitoPark mice. Taken together, our results suggest that COUP-TFII may be an important contributor to PD development and a potential therapeutic target. Parkinson’s disease (PD) is one of the major neurodegenerative diseases with increased risks in the elderly population. The patients mainly experience motor dysfunction, such as tremors, bradykinesia, rigid muscles, and impaired posture and balance. However, the underlying cause of PD is poorly defined in most cases. Understanding the etiology of PD will help prevention or treatment of this disease. Here, we reported that a transcription factor, COUP-TFII, is upregulated in the substantia nigra and dopaminergic neurons (DAs) of PD patients. Elevated expression of COUP-TFII leads to aberrant cell death of DAs, a group of neurons in the central nervous system that controls body movement. The underlying mechanism is enhanced oxidative stress due to COUP-TFII-mediated transcriptional repression of mitochondrial proteins for energy production and enzymes for detoxifying dopamine metabolites. Therefore, targeting COUP-TFII in dopaminergic neurons may be a potential therapeutic strategy for PD.

30 October 2023 in Biochemical Pharmacology
Verified
Journal Article
Closed access
HSHao-Lu Sun
Hao-Lu Sun
HBHe-Ge Bian
He-Ge Bian
XLXue-Mei Liu
Xue-Mei Liu
HZHeng Zhang
Heng Zhang
JYJie Ying
Jie Ying
JJJuan Jin
Juan Jin

27 July 2024 in Oncogene
Verified
Journal Article
Closed access
PDF file
ZJZige Jin
Zige Jin
HWHanling Wang
Hanling Wang
RTRuxian Tang
Ruxian Tang
BPBiying Pan
Biying Pan
HLHui-Ju Lee
Hui-Ju Lee
MXMafei Xu
Mafei Xu

6 August 2025 in Experimental Cell Research
Verified
Journal Article
Open access
JWJing Wang
Jing Wang
ZXZhicheng Xu
Zhicheng Xu
YZYan Zhong
Yan Zhong
JYJiaxuan Yang
Jiaxuan Yang
ZYZongle Yang
Zongle Yang
MXMafei Xu
Mafei Xu
Cell-free extrachromosomal circular DNA (eccDNA) in the plasma provides an advantage for monitoring epithelial ovarian cancer (EOC) progression. We isolated eccDNA from plasma samples of 30 EOC patients before treatment (T0 time point) and 4 healthy individuals. We followed 16 EOC patients, collecting paired eccDNA samples between the 3rd and 4th course of chemotherapy (T1) and 6 months after the last course of chemotherapy (F). The patients were divided into three groups, including complete remission (CR) group, partial remission group (PR), and relapse group (RC). We compared the normalized eccDNA count per million mapped reads (EPM) among all the groups and assessed the distribution of eccDNA on each chromosome. Then, the eccDNA within the top 5% coverage regions of each chromosome were annotated, and the top genes were analyzed for prognosis. We found that EOC patients exhibited significantly higher levels of eccDNA, with higher coverage in coding exon regions. Notably, circulating eccDNA was generally increased in the CR group, while decreased in the PR and RC group during treatment. Our results showed that the fold change of EPMs between the T1 and T0 distinguished PR and RC patients from CR patients, with area under the curve (AUC) of 0.71. Additionally, we identified two genes, SCARB1 and PDE10A, whose EPMs were able to predict prognosis in EOC patients, with AUCs of 0.86 and 0.83, respectively. Thus, our study offers valuable preliminary insights into a novel approach for predicting chemotherapy sensitivity in EOC patients, based on the trends of circulating eccDNA.